Upload
daniela-clarke
View
225
Download
1
Embed Size (px)
Citation preview
Chapter 49 Antineoplastic Drugs
Department of pharmacology
Liu xiaokang(刘小康)2010,3
Categories:
• 1) Antimetabolites: a) Folic Acid Analogs (Methotrexate, MTX). b) Pyrimidine analogs (Fluorouracil, 5-FU; Fluorodeoxyuridine; Cytarabine). d) Purine analogs (6-Mercaptopurine, 6-MP; 6-Thioguanine, 6-TG).
• 2) Alkylating agents: Nitrogen mustards; Cyclophosphamide; Thiotepa.
• 3) Natural products: Vinca alkaloids (Vincristine; Vinblastine; Vinorelbine); Paclitaxel (Taxol® )
• 4) Antiumor antibiotics: Anthracyclines (Doxorubicin hydrochloride, Daunorubicin, Bleomycin)
• 5) Miscellaneous agents: Cisplatin; Carboplatin; Asparaginase; Hydroxyurea; Corticosteroid
Mechanisms:
• Biological mechanism:
• (1) Cell cycle:
• a) Gap 1 (G1 phase). b) DNA synthesis (S
phase). c) Gap 2 (G2 phase). d) Mitosis
(M phase). G0 is a resting phase in which
the cells are not prolifering.
• (2) Cell cycle nonspecific agents (CCNSA):
• Kill proliferating cells preferentially, act on cells at all phases.
• (3) Cell cycle specific agents (CCSA):
• Act at specific phase of the cell cycle.
• Biochemic mechanism:• 1) Interfere nucleotide synthesis.• 2) Impact the structure and function of DN
A• 3) Interfere transcription and block RNA s
ynthesis.• 4) Interfere protein synthesis and functions.• 5) Change hormone lever.
Resistance mechanism
• (1) Defective activation: Cyclophosphamide requires metabolic activation, Methotrexate conversion to more active MTX-polyglutamate in cells
• (2) Increased inactivation: e.g., aldehyde dehydrogenase converse cyclophosphamide to inactive metabolite.
• (3) Altered nucleotide pools: Can occur with antimetabolites.
• (4) Altered DNA repair: Repair mechanisms increased, i.e., ability to remove cross-links, Affect the action of bleomycin and other DNA-directed drugs
• (5) Altered target: Less affinity for drug, Methotrexate (Dihydrofolate reductase changes ).
• (6) Decreased target: decreased topoisomerase II, e.g., etoposide
• (7) Gene amplification: Methotrexate (MTX) increase dihydrofolate reductase, hence Requires more MTX to block
• (8) Decreased accumulation: Decreased uptake (Methotrexate -- carrier protein decreases). Increased Efflux (Multidrug Resistance, P-Glycoprotein (gP-170) in membrane, pumps drug out)
Commonly used antineoplastic drugs
• Antimetabolites• Group Characteristics:
• (1) Resemble NORMAL substrates.• (2) Most inhibit DNA synthesis. • (3) Some inhibit RNA synthesis and/or function. (4)
Bone Marrow cell replication is profoundly inhibited.
• (5) GI toxicity great with some drugs. • (6) Highly cell cycle specific, also "phase specific", e.
g., S or M phase
Methotrexate (MTX)
• Structure:
• Mechanism of action:
• (1) Folic Acid Analogue, Carrier transport into cell. (2) Binds strongly to DHFR to deplete THF, Decreases 1-carbon transfers in Purine synthesis, Decreases [1-C-THF] intracellular which decreases dUMP dTMP, Therefore, decreases NUCLEIC ACID synthesis.
• Adverse effects:• (1) Dose limiting: a) Myelosuppression
(Thrombocytopenia and Leukopenia, Nadirs 7-10 days after Rx, Recovery 14-21 days). b) GI toxicity (Oral mucositis is early sign of GI toxicity, Severe mucositis, Small bowel ulceration & bleeding, Diarrhea -- requires cessation to prevent perforation of gut )
• (2) Nephrotoxicity: Conventional doses, infrequent toxicity; High doses, toxicity can be severe
• (3) Immunosuppression.
• (4) Hepatotoxicity.
• Clinical Uses:
• Broad range. Well established: (1) Acute Lymphoblastic Leukemia of childhood. (2) Choriocarcinoma. (3) Cancers of breast, bladder, and head & neck. (4) Useful in non-Hodgkin's lymphomas
Flurouracil (5-FU)
• Structure:
• Mechanism of action: • (1) Activated by conversion to nucleotide• (2) Inhibits DNA synthesis: Inhibition of
Thymidylate synthase—the most important mechanism of action (MOA) in rapidly growing tumors (?)
• (3) 5-FU Incorporated into RNA: Interfere with RNA processing - All types, May be most important MOA in slowly growing tumors.
• Adverse effects:
• (1) Dose limiting: a) Bone marrow -- esp. with bolus administration. Leukopenia & Thrombocytopenia (nadir 9-14 days after 5 days of Rx, recovery by day 21). b) GI Toxicity -- esp. with infusion administration. usually Stomatitis & Diarrhea 4-7 days after Rx.
• (2) Effect of route and schedule on adverse effects:
• IV bolus: myelosuppression is dominant; Prolonged Rx, may cause megaloblastic anemia
• Continuous IV Infusion: Frequently produce, stomatitis, nausea, vomiting, and diarrhea; Hepatotoxicity (elevated transaminases); myelosuppression less common
• (3) Effect of peak 5-FU concentration:
• Acute, reversible cerebellar syndrome: somnolence, ataxia of trunk or extremities, unsteady gait, slurred speech, nystagmus
• (4) Other adverse effects:
• Hyperpigmentation of skin is frequent and may be accompanied by photosensitivity; Toxic effect of radiation to skin may be enhanced; Alopecia, acute and chronic conjunctivitis, and nail changes may be observed.
• Clinical Use of 5-FU:
• (1) Single agent: Palliative in advanced colorectal carcinoma
• (2) Combination: Breast cancer; Carcinomas of ovary, stomach, pancreas
• (3) Sequential MTX + 5-FU: Head and neck cancer
Alkylating Agents • Nitrogen mustard • General view: • (1) Developed from mustard war gases of Word
War I which were highly reactive vesicants. • (2) First chemicals used for cancer Rx.• (3) Not cell cycle specific, but still more active
in dividing tissues. • (4)"Radiomimetic" -- action on DNA resembles
radiation.
• Mechanism of action:• (1) Highly reactive: Form covalent bonds
with NDA, RNA and protein
• (2) Consequences: a) DNA-DNA strand and DNA-Protein cross-links. b) Misreading of genetic code. c) DNA Chain breaks
• Adverse effects of alkylating agents: • (1) More toxic to bone marrow and gut th
an to liver and kidney, etc. (2) Infertility to both males and females. (3) Mutagenic. (4) Carcinogenic.
• Tumor resistance: • Develops slowly & may require several ge
netic / biochemical changes
• Clinical Uses:
• Wide spectrum; Lymphoreticular tissue tumors; Limited activity against sarcomas.
Cyclosphosphamide
• Mechanism of action:• Hepatic cytochrome P-450 system, enzymes pho
sphatase and phosphamidase are primary activators (hydrolyze P-N bond) to intermediate, aldophosphamide, which nonenzymatically breaks down to -- Phosphoramide mustard (bifunctional) & Acrolein
• Pharmacokinetics: • Oral bioavailability = 90-100%, IV inject
ion no local irritation • Half-life -- cyclophosphamide -- 3-10 h; al
dophosphamide -- 1.6 h; phosphoramide mustard -- 8.7 h.
• Most metabolized-- < 14% unchanged in urine.
• Clinical Applications:
• (1) Most widely used alkylating agent, in part due to availability of oral route
• (2) Active on lymphoproliferative diseases, e.g., Hodgkin's disease and Chronic lymphocytic leukemia
• (3) Significant activity vs multiple myeloma & ovarian, breast, small cell lung carcinoma
• (4) Many combinations.
• Adverse effects: • (1) Bone marrow suppression, most impo
rtant leukopenia and thrombocytopenia • (1) Nausea and vomiting said to be rare • (3) Sterile necrotizing hemorrhagic cystiti
s. Acrolein is probable cause. To minimize cyctitis--high water intake and take in AM
Natural Products
• Vinca Alkaloids• Vincristine sulfate and Vinblastine sulfat
e
• Mechanism of action:
• (1) Uptake by energy dependent carrier
• (2) Bind to tubulin in microtubules to cause their dissolution. Contrast to Taxol which stabilizes tubules.
• (3) No cross resistance between vincristine and vinblastine
• Uses:
• (1) Drug of choice for childhood leukemias in combination with prednisone
• (2) Used for lymphoreticular neoplasms, carcinomas, and sarcomas
• Adverse effects:• (1) Severe vesicant. Must be careful of IV
equipment to avoid slough.• (2) Neurotoxicity: a) Mild sensory neurop
athy with sensory impairment and paresthesia--Keep Rx. b) Severe paresthesias, loss of reflexes, ataxia, and muscle wasting-- stop Rx. c) Constipation and abdominal pain - take laxatives. e) Less hematologic effects than many other cytotoxic drugs.
Antitumor Antibiotics
• General characteristics:• (1) All interact with DNA and/or RNA, but
may also interact with other cellular substituents.
• (2) Schedule dependence: LESS "phase-specific" than antimetabolites.
• (3) Tissue necrosis is only generalizable toxicity.
• (4)All IV except bleomycin
• Doxorubicin(AdriamycinR)• Mechanism of action: • (1) DNA topoisomerase II inhibitor: Cruc
ial to DNA replication and transcription. • (2) Traditional explanations of MOA: a) i
ntercalates between base pairs of DNA and inhibits DNA-dependent RNA synthesis. b) Generates free radicals that cause membrane damage and DNA strand breaks.
• Resistance:• (1) Alterations in Topoisomerase II activi
ty. • (2) Increased inactivation of radicals: a) I
ncrease in glutathione-dependent enzymes, e.g., glutathione-peroxidase. b) Altered NADPH contents.
• (3) Increase drug efflux: a) Multi-drug resistance (MDR). b) P-glycoprotein (gP-170) pump is product of mdr gene
• Adverse effects: • Three categories of toxicity: a) Local toxi
cities. b) Acute toxicities. c) Chronic toxicity
• (1) Local Toxicity -- Extravasation • Extravasation -- DON'T! Severe local tiss
ue necrosis to point of damaging underlying structures; If occurs, treat immediately: Remove blood from IV line; Apply ice, steroid cream; Locally adm. sodium bicarbonate and hydrocortisone.
• (2) Local Toxicity -- Radiation Recall • Interaction of doxorubicin and radiation
in some tissues to produce enhanced reactions.
• Reactions include: a) Skin: ulceration and necrosis. b) Pulmonary: fibrosis and sloughing of esophageal mucosa. c) Heart, and intestinal mucosa may also be affected
• (3) Acute Toxicities • a) Hematologic: Leukopenia with nadir
7-10 days; recovery typically by 21 days; Thrombocytopenia and anemia less common
• b) If give too fast: "Histamine-release" syndrome; Cardiac arrest preceded by ECG changes
• (4) Chronic Toxicities
• a) Cardiomyopathy and congestive heart failure: require cessation of Rx after cumulative dose of 550 to 600 mg/m2; must maintain record of total dose.
• Clinical Indications: • (1) Broad spectrum anti-cancer activity. • (2) Hodgkin's disease, non-Hodgkin's lym
phomas, sarcomas, acute leukemia, and breast, lung, and ovarian carcinomas all responsive
• (3) Activity observed in bladder tumors, and carcinomas of prostate, thyroid, endometrium, head and neck, and other solid tumors
• (The end)